GLP-1s and the food chain

Two things can be true at once. On a one-quarter clock, people still hide in calories when the index falls. Smucker, Coca-Cola, and Yum can clear a screen in a week Staples leads and the S&P does not. That rotation is real. It does not tell you what Hostess is worth in 2029.

On a longer clock, GLP-1 drugs are the first medicine that reduces demand for an entire consumer category instead of treating a consequence of it. Gallup, May to June 2026: 11% of US adults say they are currently taking a GLP-1 for weight loss, up from 3% two years earlier. Fifteen percent have used one. Self-reported adult obesity is 36.4%, down from 39.9% in 2022. Numerator finds a current user in about 22% of households, grocery spend down about 4% in those homes, and roughly two-thirds stopping within six months. Circana still has US snacks at $231 billion, growing 3.2% in dollars. OC&C's volume cut is 1 to 2%. EY has put a $12 billion decade hit on snacks. PepsiCo North America foods were down 2%. Hershey has named the drugs on a call. Hostess, inside Smucker, printed volume/mix down 8 points in fiscal 2026's first quarter while the chief executive said there was no meaningful GLP-1 impact. Both sentences sat in the same filing.

Price can hide a hole for a long time

A company can lose units and still grow sales if the remaining pack costs more. The interesting quarter is the one where the missing units stop being covered by price and the margin line moves. Flat or slightly down volume with price holding is ordinary. Down volume with price also softening is the first honest print. Down volume with a fatter gross margin and a rising stock is a different story: the remaining calories are better calories, and the aisle is not dying, it is changing shape.

The long test is simple and slow. Packaged-snack volumes, from the large reporters' own volume/mix lines, need several down quarters in a row before anyone should call the category structurally smaller. Two up quarters after a dip reset that clock. Sales growing only because price rose, while units fall, still counts as the category shrinking. Sales growing because people bought more bags, while prescriptions are still compounding, would mean the drugs are scaling and the shelf is not.

Prescription growth is the other side of the same sentence. We do not own a weekly IQVIA series. Until a company prints a dated script number we can cite, this page uses the food reporters and says so.

Hostess is the exposed aisle

J.M. Smucker reported fiscal 2027's first quarter on Wednesday 26 August, with Mark Smucker and Tucker Marshall on the call. The useful line is US Retail volume/mix, and whether the year is still being guided as price and mix rather than more units. Earnings per share is a number for the quarter. It is not a picture of the aisle.

General Mills reports in September. Kraft Heinz, Mondelez, Hershey, PepsiCo, and Coca-Cola follow in October and November. Those filings are how the category clock moves. Sugar and corn sit on the strip. They are not snack volume. Beer was shrinking before the first Wegovy ad. Quick-service traffic versus ticket is the restaurant version of the same split: the check can hold while fewer people walk in.

Two things happening in one aisle

The drugs slow the stomach and make people full sooner. They eat fewer times and smaller plates. Survey work says the rest of the household often copies the plate. An 11% adult share can move a 1 to 2% category number without every user having been a Hostess regular. Protein, fibre, and smaller packs are how the remaining dollars try to stay. A single impulse pack at a checkout is both a volume problem and a plant problem. PepsiCo is trying to become the first kind of company without ceasing to be the second.

Pills you swallow and Medicare coverage are the 2027 and 2028 risk to the leak. If people stay on the drugs, Numerator's two-thirds dropout slows and OC&C's 1 to 2% becomes a floor. If they do not, the aisle keeps a rotating 11% and the work is mix, not extinction. A weekly script print cannot settle that. Prescriptions are a flow. A grocery profit and loss is a stock of people still injecting, still swallowing, and still buying dinner for a house that has started to copy the plate.

Novo Nordisk and Eli Lilly sit on the other side of every line. Prescriptions times the price they actually collect is the one number in this chain that is growing for sure.

Foodservice is traffic, not the check

Some cuts show fewer equivalent meals and pressure on the classic bundle and impulse delivery. Other cuts show trade-up: more protein, a sit-down meal instead of a drive-through. Ticket can hold while traffic is the volume line. A strong week in Yum Brands does not settle the split.

A calorie is a calorie, and beer already had demographics against it. Do not let a drug label do all the work on a category that was shrinking first. Sugar and corn will move with the Brazilian crop. They belong on a commodity strip. They do not tell you what happened to Hostess.

What a defensive week cannot do

Staples leading a down week for the index is the short truth. It will be quoted as a refutation of a five-year volume curve. It is not. A refutation would look like this: snack volumes up for two quarters while prescriptions still grow fast, or prescriptions stall, or volumes fall and margins expand and the stocks rise anyway. A Friday sector win is none of those.

The honest uncertainty is how long people stay on the drugs. If oral versions and coverage expand, and Numerator's dropout fades, the 1 to 2% volume cut is a floor and the plant network has a smaller country to feed. If dropout stays high, the aisle is a rotating 11% and the game is protein, fibre, and a smaller pack. One company's guide verb is an answer for one year. The category answer is units, Circana and Nielsen, over the next two quarters.